UW Carbone Cancer Center
UW Carbone Cancer Center
Madison, Wisconsin, United States11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, brain disorder, central nervous system cancer, central nervous system disorder, meningioma, neoplasm, nervous system disorder, tumor of meninges, vascular cancer | Recruiting | Phase 2 | 2026-10-06 | NCT07428616 | |
| Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Not applicable | 2026-09-14 | NCT07285668 | |
| Study of 18F-FFNP Breast PET/MRI | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-31 | NCT06086704 | |
| Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Not stated | 2026-08-27 | NCT07125209 | |
| Biomarkers to Detect Endocrine Therapy Resistance | Carcinoma, Lobular, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplastic Cells, Circulating, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, adenocarcinoma, breast cancer, breast disorder, breast lobular carcinoma, breast neoplasm, carcinoma, epithelial neoplasm, metastatic malignant neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-25 | NCT06067503 | |
| Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 1 | 2026-08-19 | NCT07197671 | |
| Outcomes and Cosmesis With Whole Breast Irradiation and Boost | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-07-24 | NCT06295744 | |
| Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Early phase 1 | 2026-05-26 | NCT06308913 | |
| ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT05682443 | |
| 9-ING-41 in Patients With Advanced Cancers | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Leukemia-Lymphoma, Adult T-Cell, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, T-cell leukemia, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bone cancer, bone disorder, bone neoplasm, breast disorder, breast neoplasm, cancer, central nervous system malformation, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, glioma, hematologic disorder, hereditary disease, hereditary sensory and autonomic neuropathy, immune system disorder, immunoproliferative disorder, inherited neurodegenerative disorder, intestinal disorder, kidney cancer, kidney disorder, leukemia, lung disorder, lung neoplasm, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant endocrine neoplasm, malignant glioma, malignant pancreatic neoplasm, musculoskeletal system disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuroepithelial neoplasm, neuromuscular disease, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm, peripheral nervous system disorder, polyneuropathy, primitive neuroectodermal tumor, rectal disorder, refractory malignant neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, urinary system disorder | Active, not recruiting | Phase 2 | 2026-04-03 | NCT03678883 | |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2025-09-22 | NCT05216432 |